Teva Pharmaceutical Industries Ltd (NYSE:TEVA) – Research analysts at Cantor Fitzgerald increased their FY2019 EPS estimates for shares of Teva Pharmaceutical Industries in a research note issued on Friday, November 8th. Cantor Fitzgerald analyst L. Chen now anticipates that the company will earn $2.13 per share for the year, up from their previous estimate of $2.11. Cantor Fitzgerald also issued estimates for Teva Pharmaceutical Industries’ FY2020 earnings at $2.46 EPS.
Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings results on Thursday, November 7th. The company reported $0.56 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.58 by ($0.02). Teva Pharmaceutical Industries had a positive return on equity of 15.41% and a negative net margin of 22.88%. The firm had revenue of $4.26 billion for the quarter, compared to the consensus estimate of $4.25 billion.
Several other brokerages have also issued reports on TEVA. Wolfe Research assumed coverage on Teva Pharmaceutical Industries in a research note on Friday, July 19th. They set a “peer perform” rating and a $9.00 price target for the company. SunTrust Banks dropped their price target on Teva Pharmaceutical Industries to $7.00 and set a “hold” rating for the company in a research note on Thursday, August 8th. Royal Bank of Canada reaffirmed a “hold” rating and set a $10.00 price target on shares of Teva Pharmaceutical Industries in a research note on Thursday, August 8th. Raymond James decreased their price objective on Teva Pharmaceutical Industries from $22.00 to $15.00 and set an “outperform” rating on the stock in a report on Thursday, August 8th. Finally, UBS Group set a $8.00 price objective on Teva Pharmaceutical Industries and gave the stock a “hold” rating in a report on Friday, August 16th. Five equities research analysts have rated the stock with a sell rating, fourteen have issued a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $10.83.
Shares of TEVA stock opened at $9.61 on Monday. The company has a quick ratio of 0.56, a current ratio of 0.89 and a debt-to-equity ratio of 1.62. The business has a 50-day moving average price of $7.63 and a two-hundred day moving average price of $8.82. Teva Pharmaceutical Industries has a 12-month low of $6.07 and a 12-month high of $23.97. The firm has a market cap of $10.15 billion, a P/E ratio of 3.43, a price-to-earnings-growth ratio of 0.97 and a beta of 1.73.
Large investors have recently made changes to their positions in the stock. AdvisorNet Financial Inc increased its holdings in Teva Pharmaceutical Industries by 71.3% during the 3rd quarter. AdvisorNet Financial Inc now owns 3,665 shares of the company’s stock valued at $25,000 after purchasing an additional 1,525 shares during the period. First Interstate Bank purchased a new position in Teva Pharmaceutical Industries during the 2nd quarter valued at about $28,000. Motco purchased a new position in Teva Pharmaceutical Industries during the 3rd quarter valued at about $28,000. Lindbrook Capital LLC increased its holdings in Teva Pharmaceutical Industries by 76.6% during the 3rd quarter. Lindbrook Capital LLC now owns 4,461 shares of the company’s stock valued at $31,000 after purchasing an additional 1,935 shares during the period. Finally, Pacer Advisors Inc. purchased a new position in Teva Pharmaceutical Industries during the 2nd quarter valued at about $32,000. Institutional investors own 58.20% of the company’s stock.
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.